Knight Therapeutics Inc. (TSE:GUD - Get Free Report) insider Sime Armoyan sold 15,000 shares of Knight Therapeutics stock in a transaction on Tuesday, May 7th. The shares were sold at an average price of C$5.95, for a total transaction of C$89,250.00.
Sime Armoyan also recently made the following trade(s):
- On Thursday, April 11th, Sime Armoyan sold 10,900 shares of Knight Therapeutics stock. The shares were sold at an average price of C$5.95, for a total value of C$64,855.00.
- On Monday, April 1st, Sime Armoyan purchased 6,200 shares of Knight Therapeutics stock. The shares were acquired at an average price of C$5.25 per share, for a total transaction of C$32,550.00.
- On Monday, March 25th, Sime Armoyan bought 351,000 shares of Knight Therapeutics stock. The shares were acquired at an average cost of C$5.25 per share, with a total value of C$1,842,750.00.
Knight Therapeutics Trading Up 0.9 %
GUD opened at C$5.92 on Thursday. The company has a debt-to-equity ratio of 9.25, a current ratio of 3.20 and a quick ratio of 1.79. The stock has a market capitalization of C$598.93 million, a price-to-earnings ratio of -37.00, a PEG ratio of -1,013.50 and a beta of 0.49. The business has a fifty day moving average price of C$5.56 and a 200 day moving average price of C$5.37. Knight Therapeutics Inc. has a 12 month low of C$4.35 and a 12 month high of C$5.95.
Knight Therapeutics (TSE:GUD - Get Free Report) last released its earnings results on Thursday, March 21st. The company reported C($0.03) earnings per share for the quarter, missing analysts' consensus estimates of C$0.02 by C($0.05). Knight Therapeutics had a negative return on equity of 2.14% and a negative net margin of 5.13%. The firm had revenue of C$74.20 million for the quarter, compared to analysts' expectations of C$78.37 million. Sell-side analysts expect that Knight Therapeutics Inc. will post 0.0602815 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
The ONE AI Stock to own now. (It’s not Nvidia.)
From Weiss Ratings | Ad
Don’t panic — you haven’t missed the boat on AI.
In fact, it has barely launched.
Sure, the early stages of this boom were big …
But I believe the real wealth in AI has yet to be made …
Click here to see the presentation now.
Several research firms recently commented on GUD. Royal Bank of Canada increased their price target on Knight Therapeutics from C$6.50 to C$7.00 and gave the company an "outperform" rating in a report on Friday, March 22nd. Raymond James upped their price objective on shares of Knight Therapeutics from C$7.00 to C$7.50 and gave the company an "outperform" rating in a report on Wednesday, March 6th. Finally, Stifel Nicolaus lifted their price target on shares of Knight Therapeutics from C$5.25 to C$5.40 and gave the company a "hold" rating in a research report on Wednesday, May 1st.
Get Our Latest Report on Knight Therapeutics
About Knight Therapeutics
(
Get Free Report)
Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
